BeOne Medicines (ONC) announced that the FDA has granted the company Fast Track Designation for BGB-B2033, its GPC3x4-1BB bispecific antibody for the treatment of adult patients with hepatocellular carcinoma, or HCC, with disease progression on or after prior systemic treatment. BeOne is currently conducting a global, multi-center Phase 1 clinical trial to explore the safety and anti-tumor activity of BGB-B2033, both alone and in combination with PD-1 inhibitor Tevimbra – tislelizumab -.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ONC: